ERBB2 Mutations in NSCLC: Genomic and Clinical Insights
Publication Title: ERBB2 activating mutations and co-occurring genomic alterations contribute to disease heterogeneity in patients with ERBB2-mutant lung cancer
Summary
- Question
- This study examined how different types of ERBB2 mutations contribute to the clinical and genomic characteristics of non-small cell lung cancer (NSCLC). The researchers focused on three types of ERBB2 mutations: those in the tyrosine kinase domain (TKD), extracellular domain (ECD), and transmembrane/juxtamembrane domain (TMD-JMD). They aimed to determine how these mutations affect tumor behavior and treatment outcomes, particularly with first-line chemoimmunotherapy.
- Why it Matters
- ERBB2 mutations occur in 1% to 4% of NSCLC cases and represent a target for emerging therapies. However, most approved treatments are based on tumors with TKD mutations, leaving other ERBB2 mutation types, such as ECD and TMD-JMD, less studied. Understanding how these mutations influence tumor characteristics and treatment responses could guide personalized treatment strategies and improve outcomes for patients with ERBB2-mutant NSCLC.
- Methods
- The researchers analyzed data from two large patient cohorts: the GENIE database (483 patients) and the Flatiron Health-Foundation Medicine database (286 patients). Patients with advanced NSCLC and ERBB2 mutations were categorized based on mutation type (TKD, ECD, or TMD-JMD). Clinical characteristics, co-occurring genomic alterations, and outcomes with first-line chemoimmunotherapy were compared across mutation types.
- Key Findings
- Most patients (71% to 75%) had TKD mutations, while ECD and TMD-JMD mutations accounted for 18% to 24% and 5% to 7% of cases, respectively. ECD-mutant tumors exhibited a higher tumor mutation burden and frequent co-mutations in genes like EGFR and KRAS. Progression-free survival at 12 months was higher for patients with ECD-mutant tumors (35%) compared to those with TKD mutations (18%).
- Implications
- Patients with ECD mutations had a progression-free survival rate of 35% at 12 months, compared to 18% for those with TKD mutations, suggesting that ECD-mutant patients may benefit more from chemoimmunotherapy. This underscores the need for mutation-specific treatment strategies to optimize outcomes for patients with ERBB2-mutant NSCLC.
- Next Steps
- Future research should focus on larger studies to confirm these findings and assess the effectiveness of ERBB2-targeted therapies for ECD- and TMD-JMD-mutant NSCLC. Additionally, clinical trials should consider mutation-specific approaches to improve personalized treatment options.
- Funding Information
- This research was supported by the National Institutes of Health (Yale SPORE in Lung Cancer, grant P50-CA196530). Additional support was provided by the Aron Foundation and The Anne Wojcicki Foundation.
Full Citation
Stockhammer P, El Zarif T, Schillo J, Li F, Goldberg S, Politi K, Grant M. ERBB2 activating mutations and co-occurring genomic alterations contribute to disease heterogeneity in patients with ERBB2-mutant lung cancer. Journal Of Thoracic Oncology 2026, 103708. PMID: 41932614, DOI: 10.1016/j.jtho.2026.103708.
Authors
Paul Stockhammer, MD, PhD
First AuthorClinical Fellow
Michael Grant, MD
Last AuthorAssistant Professor of Medicine (Medical Oncology)